CytoMed’s $4.3M ATM and Cord Blood Bank Acquisition Spur 28% Stock Rally

Introduction

CytoMed Therapeutics Limited (NASDAQ: GDTC) is a clinical-stage biopharmaceutical company headquartered in Singapore. Incorporated in 2018 as a spin-off from the Agency for Science, Technology and Research (A*STAR), it develops allogeneic cell-based immunotherapies targeting a range of hematological and solid cancers. Its lead candidates—CAR-γδ T cell therapy (CTM-N2D), unmodified γδ T cell therapy (CTM-GDT), and iPSC-derived γδ NKT therapy—are designed to utilize multiple antigen-recognition systems for scalable manufacturing.

Corporate Structure

CytoMed employs between 11 and 50 individuals across research, manufacturing, and corporate functions. The board is chaired by Mr. Choo Chee Kong, who has over 20 years of experience in corporate finance and governance. Dr. Lucas Luk Tien Wee, M.D., is Chief Clinical Officer and Principal Investigator for Phase I trials in Malaysia. Dr. Zeng Jieming, M.D., Ph.D., serves as Chief Scientific and Medical Officer, overseeing product development and clinical applications. The management team brings a combination of academic, clinical, and industrial experience in cell therapy and gene-vector research.

Cell therapy by National Cancer Institute

Developments and News

• August 18, 2025: CytoMed entered into an At-the-Market (ATM) Offering Program with R.F. Lafferty & Co., Inc., allowing for the sale of up to US $4.3 million of ordinary shares. The proceeds are designated for general corporate purposes, including potential acquisitions.
• August 28, 2025: CytoMed completed the acquisition of a licensed Malaysian cord blood bank (IPSC Depository Sdn Bhd) and established LongevityBank Pte Ltd to focus on autologous cell banking and cord blood-derived therapeutics. Management revealed plans for a potential equity investment of up to US $500,000 in LongevityBank.
• October 2, 2025: A collaborative research paper with The University of Texas MD Anderson Cancer Center was published, demonstrating the potential of allogeneic γδ T cells in treating acute myeloid leukemia.
• October 6–9, 2025: CytoMed exhibited its γδ T cell and CAR-γδ T cell platforms at NICE 2025 in Kuala Lumpur, engaging with oncology professionals.
• October 14, 2025: The company announced a cash bid for assets from TC BioPharm Limited, which entered administration, as part of a strategy to expand its technology portfolio.
• October 22, 2025: Executive Chairman Mr. Choo Chee Kong increased his shareholding by 105,824 shares, bringing his total stake to 21.95%.

Financial and Strategic Analysis

As of October 22, 2025, GDTC shares closed at US $3.3055, reflecting a 28.62% increase on a volume of 189,887 shares. Recent SEC filings did not disclose specific financial statements, but the initiation of the ATM program and planned investments indicate ongoing capital-raising efforts to support research, development, and scaling of manufacturing. The absence of published revenue or profitability figures highlights CytoMed’s pre-commercial stage, with the focus on advancing its pipeline assets through clinical trials.

Market Position and Industry Context

CytoMed operates within the cell therapy segment of biotechnology, where allogeneic immunotherapies are receiving attention for their potential advantages. Its focus on γδ T cells differentiates it from competitors developing traditional αβ CAR-T and iPSC-derived therapeutics. Amidst ongoing collaborations with institutions like MD Anderson and Sengkang General Hospital, CytoMed aims to validate its technologies. The global cell therapy market is expected to grow as demand for scalable solutions in treating solid tumors increases.

tl;dr

On October 22, 2025, GDTC shares rose 28.62% to US $3.3055 on substantial volume. In August, CytoMed established an ATM facility for up to US $4.3 million and acquired a Malaysian cord blood bank to form LongevityBank Pte Ltd. In October, the company published data from its collaboration with MD Anderson, initiated a bid for TC BioPharm assets, and reported an increase in shareholding by its Executive Chairman to 21.95%. These developments reflect ongoing capital efforts and a commitment to strategic expansion into oncology and autoimmune cell therapy.